Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19.

ABSTRACT:

Background

Lung cancer is among the malignancies most vulnerable to coronavirus disease 2019 (COVID-19). Eosinophils have anti-tumor and antiviral effects. Since November 2021, the omicron variant of COVID-19 has become a topic of concern; however, the impact of eosinophils on the severity and outcomes of patients with lung cancer with omicron remains uncertain. This study aimed to utilize eosinophils to predict patient outcomes and guide the prevention and monitoring of omicron.

Methods

This study performed an analysis of 284 patients with lung cancer who were hospitalized in the second hospital of Jilin University, of whom 83 patients were confirmed to have omicron infection. Depending on the eosinophil counts, patients were divided into two groups: low and high eosinophil

SUBMITTER: Hu X 

PROVIDER: S-EPMC12283595 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature